FDA-Approved Teplizumab: What We Know About Delaying Type 1 Diabetes

Teplizumab is a drug approved by the FDA to delay the onset of Type 1 diabetes in a specific group of people: those 8 years and older who have early signs of the disease but haven't yet developed symptoms. Type 1 diabetes occurs when the immune system mistakenly attacks insulin-producing cells in the pancreas. Some people have genetic markers and antibodies that indicate they're at very high risk of developing the disease in the coming years.

For example, someone like Anna Ferguson—whose older sister has Type 1 diabetes—might show antibody markers at age 5 that put her risk of developing diabetes over the next 5 years at about 75%. Teplizumab is designed for people in this 'high-risk but not yet symptomatic' window, potentially allowing them to delay the moment when insulin therapy becomes necessary.

Clinical trials have demonstrated that teplizumab helps preserve the insulin-producing cells of the pancreas. In a recent study of children and adolescents who had already developed Type 1 diabetes, those treated with teplizumab had significantly higher levels of a marker called C-peptide at week 78 compared to those who received a placebo. About 95% of patients treated with teplizumab maintained meaningful levels of this marker, compared to about 79% of those who didn't receive the drug.

This suggests the drug slows down the destruction of insulin-producing cells. However, the research also shows that teplizumab didn't significantly reduce the amount of insulin patients needed to take or change other key measures like blood sugar control and time spent in a healthy glucose range. In other words, the drug works at the cellular level, but the practical day-to-day benefits for newly diagnosed patients are still being understood.

It's important to be clear: teplizumab is not a cure for Type 1 diabetes. Rather, it's designed to delay when the disease becomes active and requires insulin treatment. For someone at high risk but not yet showing symptoms, this could mean years of living without needing daily insulin injections or pumps.

Researchers emphasize that teplizumab represents a shift in how we think about Type 1 diabetes—from treating it only after it develops to intervening earlier, when the immune attack on pancreatic cells is beginning. This is a meaningful advance, but it's a delay, not a reversal or prevention of the underlying disease process.

A survey of adults and caregivers of children who received teplizumab in 2024 found that most felt the treatment was worthwhile. About 87% of respondents reported feeling grateful to have received it, 72% believed it would help slow down the disease, and 60% felt it would make Type 1 diabetes easier to manage once it develops. More than 80% said they would recommend the treatment or make the same decision for another family member.

That said, respondents also expressed continued concern about diabetes progression. The sense of hope wasn't about avoiding Type 1 diabetes entirely, but about gaining time and potentially reducing the intensity of the disease when it eventually emerges.

Researchers are now investigating whether teplizumab can help people who have just been diagnosed with Type 1 diabetes, not just those at high risk. Scientists are also exploring how to identify which patients are most likely to benefit from the drug and how to tailor treatment decisions for individual needs.

Experts also highlight the importance of broadening access to screening for Type 1 diabetes markers in the general population. The earlier high-risk people are identified, the sooner they could potentially benefit from treatments like teplizumab. These efforts underscore a broader shift in Type 1 diabetes research toward early detection and intervention.

Origin: YouTube (Video report). Evidence: Video report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.